Cadence Pharmaceuticals (CADX) trades 13.1% lower after announcing a plan to sell $75M of common...


Cadence Pharmaceuticals (CADX) trades 13.1% lower after announcing a plan to sell $75M of common stock on a market cap sitting south of $300M. Undeterred by the firm's new public offering of shares, Colins Stewart initiates coverage with a Buy rating and a lofty $7 price target.

From other sites
Comments (1)
  • nicolas2010
    , contributor
    Comments (2) | Send Message
     
    Cadence is CADX, not CDX
    14 Nov 2011, 12:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs